VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful...
Clinical Trial
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing...
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the...
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A...
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including...
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue...
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives...
Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / February...
SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced...
FSD Pharma Announces Debt Settlement
TORONTO, ON / ACCESSWIRE / February 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical...
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying...
Applied Therapeutics Announces $100 Million Private Placement
Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with...
Ocugen Clinical Showcase Webcast Now Available
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
PDUFA target action date of August 28, 2024 MAA validated and accepted for review by EMA in December 2023 NEW...
Volta Medical Receives CE Mark for AF-Xplorer™ Decision support solution to Simplify Complex Atrial Fibrillation Procedures
Proprietary AI companion technology assists electrophysiologists by reducing ambiguity in mapped atrial fibrillation (AF) patterns MARSEILLE, France, Feb. 28, 2024...
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024HIGH POINT, N.C., Feb. 28, 2024...